Sonus Pharmaceuticals/Abbott Labs
This article was originally published in The Gray Sheet
Abbott will continue to manufacture Sonus' ultrasound contrast agent EchoGen until mid-2002, but will return to Sonus the marketing rights to the product for no cost under an agreement announced April 5. The companies are currently negotiating "appropriate amendments" to the existing manufacturing agreement
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.